

### **KHRC Medication and Penalty Regulation Changes for standardbred racing**

*Please be advised that the following changes to 811 KAR 1:090 and 811 KAR 1:095 are anticipated to go into effect on September 4, 2012:*

1. **The use of adjunct bleeder medications will be prohibited within 24 hours of a race.**

2. **The following thresholds and withdrawal guidelines have been adopted:**

(The complete Withdrawal Guidelines and Medication Classifications are attached.)

- Diclofenac 5 ng/ml serum
- Firocoxib 20 ng/ml serum (Veterinarians are encouraged to review the withdrawal guidelines for firocoxib)
- Methocarbamol 1 ng/ml serum
- Glycopyrrolate 1 ng/ml urine OR 3.5 pcg/ml serum

3. **The following medications have been assigned penalty classifications:**

Class A: Cannabinoids (synthetic), Cobratoxin, Conotoxin, Dermorphin, Inositol Trispyrophosphate (ITPP), Levamisole\*/Tetramisole, Methylene dioxypyrovalene (MDVP or 'Bath Salts')

Class C: Diclofenac, Firoxocib

\* Levamisole has been assigned Penalty classification A in light of its documented stimulatory effect on the nervous system. The KHRC recognizes that Levamisole has legitimate therapeutic use and does not wish to prevent horses from receiving appropriate veterinary care. Rather, the KHRC intends that Levamisole not be administered in proximity to a race. Further, the KHRC does not provide withdrawal guidance for substances associated with a Class A penalty, but does wish to inform veterinarians and horsemen that Levamisole is currently not being detected in post-race samples. To the extent that Levamisole is currently being administered, that administration would not result in a rule violation.

Individuals having questions or concerns are welcome to contact Dr. Mary Scollay at: 859 246-2040 or [mary.scollay@ky.gov](mailto:mary.scollay@ky.gov)